Innoviva reported strong revenue from its diversified core royalty business despite challenging market conditions. The acquisitions of Entasis and La Jolla have given the company a strong footprint in the hospital and infectious disease space.
RELVAR®/BREO® ELLIPTA® global net sales grew slightly compared to third quarter 2021, with U.S. net sales growth compensating for foreign currency changes and a slowdown in non-U.S. markets.
ANORO® ELLIPTA® global net sales decreased by 15% compared to third quarter of 2021 mainly due to pricing pressures and foreign currency changes.
Innoviva advanced its strategy with the acquisitions of Entasis and La Jolla, giving it a strong footprint in the hospital and infectious disease space.
The company remains committed to a disciplined, thoughtful, and thorough approach to capital allocation.
No forward guidance was provided in the press release.
Analyze how earnings announcements historically affect stock price performance